Moderate to Severe Ulcerative Colitis (DBCOND0069179)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Tofacitinib	A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.	Non-receptor tyrosine-protein kinase TYK2target Cytochrome P450 3A4enzyme Cytochrome P450 2C19enzyme Tyrosine-protein kinase JAK2target Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK3target Albumincarrier

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04090411	A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis	RVT-3101	treatment	2	completed
NCT04700449	A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)	No drug interventions	treatment	2	completed
NCT05486104	Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis	No drug interventions	treatment	2	recruiting
NCT03627052	A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis	Itacitinib	treatment	2	withdrawn
NCT04879966	A Cohort Study Comparing IFX to CS for Moderate to Severe UC	Infliximab	Not Available	Not Available	recruiting
NCT02092389	Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo	No drug interventions	Not Available	Not Available	terminated